Piper Sandler Reaffirms Overweight Rating for Ardelyx (NASDAQ:ARDX)

Piper Sandler restated their overweight rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $15.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on the company. StockNews.com cut Ardelyx from a hold […]

Related Keywords

United States ,Piper Sandler ,Elizabetha Grammer ,Michael Raab ,Leerink Partnrs ,Campbell Co Investment Adviser ,Citigroup ,Ardelyx Inc ,Charles Schwab Investment Management Inc ,Vanguard Group Inc ,Securities Exchange Commission ,Capital Partners ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Schwab Investment Management ,Adage Capital Partners ,Ardelyx Daily ,